Jason Weil practices law in the area of intellectual property (IP), with a focus on patent litigation.

Dr. Weil’s practice encompasses a range of technologies, including monoclonal antibody therapies, biosimilars, DNA diagnostics and medical devices.

Dr. Weil was part of the team that represented pharmaceutical companies and an inventor in patent infringement actions in the District of Delaware and the District of New Jersey. The accused products in those cases were recently approved monoclonal antibody drugs that manipulated the body’s immune system to treat cancer. The cases settled on favorable terms for the client.

Dr. Weil successfully represented Cornell University before the Patent Trial and Appeal Board (PTAB), leading to denial of institution of three petitions for inter partes review challenging Cornell patents related to Cornell’s DNA detection technology.

In addition to his patent litigation work, Dr. Weil has successfully advocated for pro bono clients on a variety of matters. He has represented abused and neglected children before the Family Court in Philadelphia as a volunteer attorney with the Support Center for Child Advocates. Dr. Weil also worked as a volunteer attorney with the Pennsylvania Immigration Resource Center to successfully represent a Somalian man seeking asylum before the Immigration Court.

Prior to joining Akin Gump, Dr. Weil served as a law clerk to The Honorable Richard Linn of the United States Court of Appeals for the Federal Circuit.

In 2011, Dr. Weil earned his J.D. with highest honors from the George Washington University Law School, where he was an associate member of the George Washington Law Review and a member of the Order of the Coif. While in law school, he served as an intern/analyst at the National Commission on the BP Deepwater Horizon Oil Spill and Offshore Drilling and as a judicial intern to The Honorable T.S. Ellis III of the United States District Court for the Eastern District of Virginia.

Prior to attending law school, Dr. Weil earned his Ph.D. in biology from the Johns Hopkins University and his B.S. in biotechnology from the Rochester Institute of Technology. His graduate work focused on understanding the cellular mechanism of nonsense-mediated mRNA decay.

Representative Work

Dr. Weil’s recent egagements include:

  • currently representing pharmaceutical companies in correction of inventorship action (D. Mass.)
  • currently representing an innovator pharmaceutical company and a university in one of the first biosimilar patent challenges
  • currently representing a university and a life science research products manufacturer in inter partes review proceedings related to DNA sequencing technology (PTAB)
  • currently representing a life science research products manufacturer in a patent infringement action related to inventory business methods (S.D. Cal.)
  • representing a pharmaceutical companies in patent infringement suits involving methods of treatment for cancer (D. Del.); succeeded in obtaining a favorable settlement
  • representing a pharmaceutical companies in patent infringement suits involving antibody drugs for use in treating cancer (D.N.J.); succeeded in obtaining a favorable settlement
  • representing a pharmaceutical company in an appeal after successful defense against claims in multiple ANDA litigations (S.D.N.Y.); prevailed on appeal to the Federal Circuit.